<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2954-4122</journal-id>
<journal-title><![CDATA[Archivos de neurociencias (México)]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Neurocien. (Mex.)]]></abbrev-journal-title>
<issn>2954-4122</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suárez"]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2954-41222024000400181</article-id>
<article-id pub-id-type="doi">10.24875/anc.m24000030</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tratamiento con cannabinoides para la demencia rápidamente progresiva]]></article-title>
<article-title xml:lang="en"><![CDATA[Cannabinoid treatment for rapidly progressive dementia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vázquez-Barreto]]></surname>
<given-names><![CDATA[Mareli]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Celedón-Suárez]]></surname>
<given-names><![CDATA[Julián]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tapia-Hernández]]></surname>
<given-names><![CDATA[Héctor M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Coffeen]]></surname>
<given-names><![CDATA[Ulises]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General de México Dr. Eduardo Liceaga Servicio de Anestesiología ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Médico Nacional Siglo XXI Hospital de Especialidades Servicio de Neurofisiología Clínica]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz División de Investigaciones en Neurociencias ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<volume>29</volume>
<numero>4</numero>
<fpage>181</fpage>
<lpage>186</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2954-41222024000400181&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2954-41222024000400181&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2954-41222024000400181&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La demencia rápidamente progresiva (DRP) es un trastorno de deterioro cognitivo que avanza rápidamente y conduce a demencia en menos de 2 años. En la actualidad no existe un tratamiento estándar para la DRP; sin embargo, se ha propuesto el uso de la medicina cannábica para el tratamiento de la demencia en general. Mujer de 45 años con diagnóstico actual de demencia rápidamente progresiva, epilepsia y secuelas de evento vascular cerebral. Posterior a la valoración, se inicia tratamiento paliativo con modificaciones en la dieta más uso de derivados cannabinoides, principalmente cannabidiol (CBD), con dosis inicial de 20 mg/día, más dosis de rescate en caso de crisis epilépticas. Durante el inicio del tratamiento y en los meses posteriores se presentó mejoría del estado de la paciente, con atenuación de la somnolencia y limitación de las crisis epilépticas, además de mostrar mejoría clínica en la escala ESAS en áreas como estreñimiento, insomnio, apetito, dolor, convulsiones y reflejo de Moro. También se logró una disminución de las dosis de levetiracetam (40%) y de valproato (50%). En estudios tanto básicos como clínicos se ha demostrado una eficacia en la reducción de la neurotoxicidad y la neuroinflamación, y efectos anticonvulsivos, de los derivados cannabinoides, principalmente del CBD, por lo que su uso en conjunto con las terapias convencionales podría reducir el daño de manera temprana en pacientes con condiciones neurodegenerativas y limitar el avance de la enfermedad, proporcionando así una mejor calidad de vida.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Rapidly progressive dementia (RPD) is a cognitive impairment disorder that progresses rapidly, leading to dementia in less than 2 years. Currently, there is no standard treatment for RPD. However, the use of cannabis medicine has been proposed for the treatment of dementia in general. A 45-year-old woman with a current diagnosis of rapidly progressive dementia, epilepsy sequelae of cerebral vascular event. After the assessment, palliative treatment is initiated with dietary modifications plus the use of cannabinoid derivatives, mainly cannabidiol (CBD), with an initial dose of 20 mg per day, plus rescue doses in case of epileptic seizures. During the beginning of treatment and in the subsequent months, there was an improvement in the patient's condition, with attenuation of drowsiness and limitation of epileptic seizures, in addition to showing clinical improvement according to the ESAS scale in areas such as constipation, insomnia, appetite, pain, convulsions, and Moro reflex. Moreover, a reduction in the dose of levetiracetam (40%) and valproate (50%) was achieved. Both basic and clinical studies have demonstrated efficacy in reducing neurotoxicity, neuroinflammation, and anticonvulsant effects of cannabinoid derivatives, mainly CBD, so its use in conjunction with conventional therapies could reduce damage early in patients with neurodegenerative conditions and limit the progression of the disease, thus providing a better quality of life.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Demencia rápidamente progresiva]]></kwd>
<kwd lng="es"><![CDATA[CBD]]></kwd>
<kwd lng="es"><![CDATA[THC]]></kwd>
<kwd lng="es"><![CDATA[Cannabinoides]]></kwd>
<kwd lng="en"><![CDATA[Rapidly progressive dementia]]></kwd>
<kwd lng="en"><![CDATA[CBD]]></kwd>
<kwd lng="en"><![CDATA[THC]]></kwd>
<kwd lng="en"><![CDATA[Cannabinoids]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hermann]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Zerr]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rapidly progressive dementias —aetiologies, diagnosis and management]]></article-title>
<source><![CDATA[Nat Rev Neurol]]></source>
<year>2022</year>
<volume>18</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>363-76</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Day]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rapidly progressive dementia]]></article-title>
<source><![CDATA[Continuum (Minneap Minn)]]></source>
<year>2022</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>901-36</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and outcomes of rapidly progressive dementia:A retrospective cohort study in a neurologic unit in China]]></article-title>
<source><![CDATA[BMC Geriatr]]></source>
<year>2023</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guevara Valmaña]]></surname>
<given-names><![CDATA[OI]]></given-names>
</name>
<name>
<surname><![CDATA[Venzor Castellano]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Jiménez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Demencia rápidamente progresiva, sobre el reporte de un caso de Creutzfeldt-Jakob]]></article-title>
<source><![CDATA[Rev Fac Med]]></source>
<year>2020</year>
<page-range>63</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tayyebi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Malakouti]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Shariati]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kamalzadeh]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Covid-19-associated encephalitis or Creutzfeldt–Jakob disease:A case report]]></article-title>
<source><![CDATA[Neurodegener Dis Manag]]></source>
<year>2021</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>29-34</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dubey]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ghosh]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dubey]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chakraborty]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Roy]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of SARS-CoV-2 infection on the cognitive functioning of patients with pre-existing dementia]]></article-title>
<source><![CDATA[J Alzheimers Dis Rep]]></source>
<year>2023</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>119-28</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<collab>American Psychiatric Association</collab>
<source><![CDATA[Manual diagnóstico y estadístico de los trastornos mentales DSM-5®]]></source>
<year>2014</year>
<edition>5ta ed</edition>
<publisher-loc><![CDATA[Buenos Aires ]]></publisher-loc>
<publisher-name><![CDATA[Médica Panamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peprah]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[McCormack]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Medical cannabis for the treatment of dementia:A review of clinical effectiveness and guidelines]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Ottawa ]]></publisher-loc>
<publisher-name><![CDATA[CADTH]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Moreno]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[González-Cuevas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Navarro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The pharmacology of the endocannabinoid system:functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction]]></article-title>
<source><![CDATA[Addict Biol]]></source>
<year>2008</year>
<volume>13</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>160-87</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shohami]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen-Yeshurun]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Magid]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Algali]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mechoulam]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Endocannabinoids and traumatic brain injury]]></article-title>
<source><![CDATA[Br J Pharmacol]]></source>
<year>2011</year>
<volume>163</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1402-10</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mechoulam]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Shohami]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Endocannabinoids and traumatic brain injury]]></article-title>
<source><![CDATA[Mol Neurobiol]]></source>
<year>2007</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>68-74</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cristino]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bisogno]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Di Marzo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabinoids and the expanded endocannabinoid system in neurological disorders]]></article-title>
<source><![CDATA[Nat Rev Neurol]]></source>
<year>2019</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>9-29</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bilbao]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Spanagel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medical cannabinoids:A pharmacology-based systematic review and meta-analysis for all relevant medical indications]]></article-title>
<source><![CDATA[BMC Med]]></source>
<year>2022</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Tsien]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Whalley]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Devinsky]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabinoids and epilepsy]]></article-title>
<source><![CDATA[Neurotherapeutics]]></source>
<year>2015</year>
<volume>12</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>747-68</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Biegon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabinoids as neuroprotective agents in traumatic brain injury]]></article-title>
<source><![CDATA[Curr Pharm Des]]></source>
<year>2004</year>
<volume>10</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>2177-83</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rajah]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kolb]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Saber]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Fadel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The endocannabinoid system and stroke:A focused review]]></article-title>
<source><![CDATA[Brain Circ]]></source>
<year>2019</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scharf]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Ebbert]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Endocannabinoids and stroke prevention:Review of clinical studies]]></article-title>
<source><![CDATA[Cannabis Cannabinoid Res]]></source>
<year>2020</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>6-11</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández-Ruiz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Moro]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Orgado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabinoids in neurodegenerative disorders and stroke/brain trauma:From preclinical models to clinical applications]]></article-title>
<source><![CDATA[Neurotherapeutics]]></source>
<year>2015</year>
<volume>12</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>793-806</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bosnjak Kuharic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Markovic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Brkovic]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Jeric Kegalj]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rubic]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Vuica Vukasovic]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabinoids for the treatment of dementia]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2021</year>
<volume>2021</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nasreddine]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Montreal Cognitive Assessment (MoCA)]]></article-title>
<source><![CDATA[Version 8.1. [Internet]]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Québec ]]></publisher-loc>
<publisher-name><![CDATA[MoCA Cognition]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramírez Benítez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Batería luria inicial y desarrollo de las funciones psicológicas superiores]]></article-title>
<source><![CDATA[Acción Psicológica]]></source>
<year>2015</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>69-77</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Page]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Kloner]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Carriker]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Martel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medical marijuana, recreational cannabis, and cardiovascular health:A scientific statement from the American Heart Association]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2020</year>
<volume>142</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abate]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Uberti]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tambaro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential and Limits of Cannabinoids in Alzheimer's Disease Therapy]]></article-title>
<source><![CDATA[Biology (Basel)]]></source>
<year>2021</year>
<volume>10</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1-21</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
